A new era in HIV treatment may be dawning as scientists harness CRISPR gene-editing to completely remove the virus from infected cells. This cutting-edge approach targets the root cause of HIV infection by snipping out viral DNA that current medications can’t reach.
Early clinical trials by Excision BioTherapeutics have demonstrated the safety of their EBT-101 treatment in humans, though efficacy results remain modest. Researchers emphasize that while these developments are promising, much work remains to optimize delivery methods and ensure complete elimination of HIV reservoirs throughout the body.
